SUMMER FOUNTAIN: Open Payments
NPI 1922875327 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,817 in 75 payments from 27 companies in 2025. Trend: 2023 $128 · 2024 $3,104 · 2025 $1,817
Food & beverage: $1,817
| Company | Payments | Amount |
|---|---|---|
| SK Life Science, Inc. | 9 | $278 |
| UCB, Inc. | 9 | $235 |
| Novartis Pharmaceuticals Corporation | 6 | $126 |
| ACADIA Pharmaceuticals Inc | 5 | $125 |
| JAZZ PHARMACEUTICALS INC. | 5 | $104 |
| Alnylam Pharmaceuticals Inc. | 3 | $86 |
| Janssen Biotech, Inc. | 4 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| GENZYME CORPORATION | 2 | $65 |
| Merz Pharmaceuticals, LLC | 2 | $62 |
Products named: Zilbrysq, KESIMPTA, EPIDIOLEX, NUPLAZID, AMVUTTRA, HYQVIA, Briviact, Xeomin.
Industry payments across AL — which companies pay providers there.
